盐酸氨溴索对早产儿肺透明膜病的预防作用

Ambroxol prevents premature infants from neonatal pulmonary hyaline membrane disease

目的探讨盐酸氨溴索对早产儿肺透明膜病（PHMD）的预防效果。方法将280例早产儿随机分为两组,每组140例。两组常规治疗相同,在此基础上,观察组予盐酸氨溴索30mg/kg.d-1,q8h,1～3天。结果观察组PHMD的发生率（10.00%）显著低于对照组（26.43%）,χ^2=12.68,P〈0.01。观察组发生PHMD后的患者呼吸困难程度、X线分级较轻,机械通气使用率低,与对照组比较差异有高度显著性（P均〈0.01）。且病死率（7.14%）低于对照组（43.24%）,χ^2=5.98,P〈0.05。结论产后立即用盐酸氨溴索对预防早产儿PHMD疗效显著。

Objective To outline the clinical effects of Ambroxol on preventing and treating premature infants with neonatal pulmonary hyaline membrane disease （PHMD）. Methods 280 patients with premature infants were randomly allocated to two groups, 140 in each group. The two groups received the same conventional treatment, in addition, the observation group received Ambroxol 30 mg/kg·d^-1, qSh, 1 ～ 3 days. Results In the observation group, the incidence of PHMD （10.00%） was statistically lower than the control group （26.43%）, X^2 = 12.68, P 〈0.01. After the occurrence of PHMD, the dyspnea degree, the X ray classification and the use of mechanical ventilation were lower in patients of the observation group, there were statistically significant differences, compared to the control group （ P 〈0.01）. And the mortality （7.14%） in the observation group was lower than the control group （43.24 % ）,X^2 =5.98, P 〈 0.05. Conclusion A prompt use of Ambroxol is effective in preventing and treating premature infants with PHMD.